Key Highlights
• AMGN shares rose 2.62% intraday to $370.80.
• A federal judge granted a preliminary injunction blocking Colorado's price cap on Amgen's rheumatoid arthritis drug Enbrel.
• The ruling reinforces patent protections and eases concerns that similar state-level pricing legislation could spread.
• Amgen reported first-quarter earnings per share of $5.15, above estimates of $4.77.
Legal Win Removes Pricing Overhang
Amgen Inc. (NASDAQ:AMGN) shares gained Thursday, outperforming the broader healthcare sector after a federal judge granted a preliminary injunction blocking Colorado's first-of-its-kind price cap on Enbrel, the company's blockbuster rheumatoid arthritis drug. The ruling removes a significant pricing overhang that had weighed on sentiment.
Amgen is a Thousand Oaks, California-based global biopharmaceutical pioneer discovering, developing, manufacturing and delivering therapeutics across oncology, cardiovascular disease, inflammation, bone health, nephrology and rare diseases, with a portfolio featuring blockbuster medicines including Prolia, Repatha, Otezla, Enbrel, Evenity and Tepezza.
Earnings Beat and Pipeline Optimism Add Support
The legal victory reinforces patent protections for Enbrel and eases broader fears that state-level drug pricing legislation could spread to other jurisdictions. The gains also build on Amgen's strong first-quarter results, with earnings per share of $5.15 against estimates of $4.77, alongside pipeline optimism around MariTide and olpasiran, even as a regulatory setback for Tavneos in Europe and a New England Journal of Medicine trial retraction remain lingering headwinds.
Amgen currently trades at a market capitalization of approximately $200.12 billion, with a price-to-earnings ratio near 16.8 and a dividend yield of 2.64%.
Conclusion
The court ruling blocking Colorado's Enbrel price cap represents a meaningful legal win for Amgen, removing a key pricing risk while reinforcing broader patent protections across its portfolio. Combined with a strong first-quarter earnings beat, the ruling adds to a constructive near-term narrative even as some regulatory and clinical headwinds persist.
This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.






Please wait processing your request...